Patents by Inventor Heinz-Werner Kleemann

Heinz-Werner Kleemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7932416
    Abstract: Pentafluorosulfanyl-benzenes according to Formula (I): a process for their preparation and their use as valuable synthetic intermediates for preparing, for example, medicaments, diagnostic aids, liquid crystals, polymers, pesticides, herbicides, fungicides, nematicides, parasiticides, insecticides, acaricides and arthropodicides.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: April 26, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Remo Weck
  • Publication number: 20110015167
    Abstract: TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a better understanding of TRPC ion channels in cells and beyond. The present invention provides a pharmacological tool compound that allows to study TRPC ion channels due to its discriminating inhibition of TRPC subfamilies. In the present invention, norgestimate is shown to selectively inhibit TRPC3, TRPC6 and TRPC7.
    Type: Application
    Filed: October 14, 2008
    Publication date: January 20, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Susanne Miehe, Heinz-Werner Kleemann, Carsten Struebing
  • Publication number: 20100204206
    Abstract: Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them The present invention relates to di(hetero)arylcyclohexane derivatives of the formula I, in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 3, 2009
    Publication date: August 12, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Thomas BOHME, Uwe GERLACH, Dirk GRETZKE, Heinz-Werner KLEEMANN, Stefania PFEIFFER-MAREK, Henning VOLLERT, Jean-Michel ALTENBURGER, Sergio MALLART
  • Patent number: 7772262
    Abstract: The present invention relates to substituted benzoylguanidines of the formula I: in which R1 to R8 and X and Y are as described in the specification, and their pharmaceutically acceptable salts are substituted acylguanidines as inhibitors of the cellular sodium-proton antiporter (Na+/H+ exchanger, NHE).
    Type: Grant
    Filed: May 14, 2007
    Date of Patent: August 10, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventor: Heinz-Werner Kleemann
  • Patent number: 7763661
    Abstract: This invention relates to novel substituted pentafluorosulfanylbenzenes of the formula I: and/or salts thereof as claimed, for use as a synthetic intermediates for preparing medicaments, diagnostic aids, liquid crystals, pesticides, herbicides, fungicides, nematicides, parasiticides, insecticides, acaricides, arthropodicides and polymers.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: July 27, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Remo Weck
  • Patent number: 7659429
    Abstract: A process for preparing 4-pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings indicated in the specification. The compounds of formula I are NHE1 inhibitors and can be employed, for example, for the treatment of cardiovascular disorders.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: February 9, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Gerrit Schubert, Heinz-Werner Kleemann
  • Publication number: 20100016272
    Abstract: The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired.
    Type: Application
    Filed: June 17, 2009
    Publication date: January 21, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Hartmut STROBEL, Paulus WOHLFART, Heinz-Werner KLEEMANN, Gerhard ZOLLER, David William WILL
  • Publication number: 20100016337
    Abstract: The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired.
    Type: Application
    Filed: June 17, 2009
    Publication date: January 21, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Hartmut STROBEL, Paulus WOHLFART, Heinz-Werner KLEEMANN, Gerhard ZOLLER, David William WILL
  • Patent number: 7638521
    Abstract: The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: December 29, 2009
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Jean-Christophe Carry, Pascal Desmazeau, Serge Mignani, Jean Bouquerel, Arielle Genevois-Borella, Baptiste Ronan
  • Patent number: 7622611
    Abstract: Pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings stated in the claims, are suitable, for example, as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: November 24, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventor: Heinz-Werner Kleemann
  • Patent number: 7589117
    Abstract: The present invention relates to the novel isoindolone derivatives of the formula I in which R1 to R6 have the meanings stated in the claims. The inventive compounds are suitable as antiarrhythmic medicaments with a cardioprotective component for infarction prophylaxis and infarction treatment and for the treatment of angina pectoris. They also inhibit in a preventive manner the pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure.
    Type: Grant
    Filed: March 1, 2006
    Date of Patent: September 15, 2009
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Armin Hofmeister, Jean-Christophe Carry, Baptiste Ronan, Serge Mignani, Antony Bigot
  • Publication number: 20090203761
    Abstract: The present invention relates to processes for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl)acetylguanidine derivatives of the formula I via 3-hydroxy-2,3-dihydro-1H-isoindol-1-one derivatives or 3-(2-carbamoylphenyl)-acrylic ester derivatives as intermediates, to a process for optical resolution, and to intermediates of the process according to the invention.
    Type: Application
    Filed: April 2, 2009
    Publication date: August 13, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gerrit SCHUBERT, Joerg RIEKE-ZAPP, Johannes KEIL, Heinz-Werner KLEEMANN, Reda HANNA, Bao-Guo HUANG, Xiao-Dong WU, Yves GOURAUD
  • Publication number: 20090143473
    Abstract: Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids. The active compounds identified as inhibitors of the cellular Na+/H+ exchanger (NHE) are used for the production of a medicament for the normalization of serum lipids. They are used for the production of a medicament for lowering the blood lipid level and illnesses caused thereby, as well as the endothelial dysfunction syndrome and illness caused thereby.
    Type: Application
    Filed: February 3, 2009
    Publication date: June 4, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hans Jochen LANG, Hans-Willi JANSEN, Jan-Robert SCHWARK, Heinz-Werner KLEEMANN, Oliver JUNG, Hans-Ludwig SCHAFER, Wolfgang LINZ, Werner KRAMER, Bernward SCHOLKENS, Eugen FALK
  • Patent number: 7531663
    Abstract: The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: May 12, 2009
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Jean-Christophe Carry, Pascal Desmazeau, Serge Mignani, Jean Bouquerel, Arielle Genevois-Borella, Baptiste Ronan
  • Patent number: 7531569
    Abstract: A method and apparatus for preventing board warpage during the application and curing or drying of liquid epoxies, or the like, on printed circuit boards using a clamping fixture assembly, which includes at least one clamping fixture support and at least one clamping fixture overlay. If desired, a plurality of printed circuit boards may be processed using an appropriate clamping fixture assembly. Furthermore, the clamping fixture may be constructed so a slight bow or curvature thereof can counter either a convex or concave bow or curvature of the printed circuit board. In the method, at least one printed circuit board is mounted to a clamping fixture support whereby a clamping fixture overlay is placed on top of the first printed circuit board.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: May 12, 2009
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Gerrit Schubert, Joerg Rieke-Zapp, Johannes Keil, Heinz-Werner Kleemann, Reda Hanna, Bao-Guo Huang, Xiao-Dong Wu, Yves Gouraud
  • Publication number: 20090036704
    Abstract: A process for preparing 4-pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings indicated in the specification. The compounds of formula I are NHE1 inhibitors and can be employed, for example, for the treatment of cardiovascular disorders.
    Type: Application
    Filed: October 9, 2008
    Publication date: February 5, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Gerrit Schubert, Heinz-Werner Kleemann
  • Patent number: 7449594
    Abstract: A process for preparing 4-pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings indicated in the specification. The compounds of formula I are NEH1 inhibitors and can be employed, for example, for the treatment of cardiovascular disorders.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: November 11, 2008
    Assignee: Sanofi-aventis Deutschland GmbH
    Inventors: Gerrit Schubert, Heinz-Werner Kleemann
  • Publication number: 20080234317
    Abstract: The present invention comprises the use of pharmaceutical compositions that are effective in the inhibition of the Na+/H+ exchanger, subtype 5 (NHE-5) as inhibitors of cellular NHE-5 enhance long term potentiation (LTP) and are therefore effective in the treatment of memory impairments, dementing disorders, and for improving memory.
    Type: Application
    Filed: March 12, 2008
    Publication date: September 25, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Heinz-Werner KLEEMANN, Hans-Jochen LANG, Uwe HEINELT, Armin HOFMEISTER, Holger GAUL, Ulrich Hendrich SCHROEDER, Klaus REYMANN
  • Publication number: 20080200553
    Abstract: Pentafluorosulfanylbenzoylguanidines of the formula I and II in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.
    Type: Application
    Filed: April 14, 2008
    Publication date: August 21, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventor: Heinz-Werner KLEEMANN
  • Publication number: 20080146673
    Abstract: Pentafluorosulfanylbenzoylguanidines of formula I wherein R1 to R4 have the meanings stated in the claims, are suitable, for example, as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.
    Type: Application
    Filed: January 11, 2008
    Publication date: June 19, 2008
    Applicant: sanofi-aventis Deutschland GmbH
    Inventor: Heinz-Werner KLEEMANN